OncoSec Medical (NSDQ:ONCS) said today that its DNA-based intratumoral cancer immunotherapy, pIL-12, won orphan drug designation from the FDA for the treatment of unresectable metastatic melanoma.
The drug, tavokinogene telsaplasmid, is the biologic agent delivered using OncoSec’s ImmunoPulse IL-12 electroporation device.
Get the full story at our sister site, Drug Delivery Business News.